CD19 and hematologic disorder: CD19/CD20 dual-target CAR T-cells have been prepared at multiple centers and proven to be feasible (20–22). Of the various CAR T-cell therapies that are known, T-cells engineered with CAR-targeting CD19 have shown remarkable efficacy in patients with hematological malignancies, such as B-cell acute lymphoblastic leukemia (23–25) and B-cell lymphoma (26–28).